Patents by Inventor Jingrong Cao

Jingrong Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective inhibitors of rock protein kinase and uses thereof
    Publication number: 20070270386
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Application
    Filed: May 10, 2007
    Publication date: November 22, 2007
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20070265263
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Application
    Filed: May 16, 2007
    Publication date: November 15, 2007
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Oing Tang, Alex Aronov
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7253187
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 7, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Qing Tang, Alex Aronov
  • Azaindazoles useful as inhibitors of kinases
    Publication number: 20070179177
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Application
    Filed: November 15, 2006
    Publication date: August 2, 2007
    Inventors: Guy Brenchley, Jean-Damien Charrier, Steven Durrant, Ronald Knegtel, Sharn Ramaya, Shazia Sadig, Jingrong Cao
  • Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases
    Patent number: 7169798
    Abstract: The present invention provides compounds of formula I: where R1 is H, CONH2, T(n)-R, or T(n)-Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Guy Bemis, Anne-Laure Grillot, Mark Ledeboer, Francesco G. Salituro, Edmund Harrington, Huai Gao, Christopher Baker, Jingrong Cao, Michael Hale
  • Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
    Patent number: 7084159
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative o thereof, wherein A, B, Ra, R1, R2, R3, and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: August 1, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jeremy Green, Young-Choon Moon, Jian Wang, Mark Ledeboer, Edmund Harrington, Huai Gao
  • Bicyclic inhibitors of Rho kinase
    Publication number: 20060122185
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of ROCK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: November 22, 2005
    Publication date: June 8, 2006
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Huai Gao, Cornelia Forster
  • Pyrazole compositions useful as inhibitors of erk
    Patent number: 7056944
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Azaindoles useful as inhibitors of rock and other protein kinases
    Publication number: 20060003968
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: April 4, 2005
    Publication date: January 5, 2006
    Inventors: Jeremy Green, Andrew Miller, Juan-Miguel Jimenez, Craig Marhefka, Jingrong Cao, John Court, Upul Bandarage, Huai Gao, Suganthini Nanthakumar
  • Isoxazole compositions useful as inhibitors of ERK
    Publication number: 20050090536
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: July 24, 2003
    Publication date: April 28, 2005
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao, Robert Mashal
  • Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases
    Publication number: 20050026967
    Abstract: The present invention provides compounds of formula I: where R1 is H, CONH2, T(n)—R, or T(n)—Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: February 13, 2004
    Publication date: February 3, 2005
    Inventors: Jeremy Green, Guy Bemis, Anne-Laure Grillot, Mark Ledeboer, Francesco Salituro, Edmund Harrington, Huai Gao, Christopher Baker, Jingrong Cao, Michael Hale
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20040229875
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: February 3, 2004
    Publication date: November 18, 2004
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Qing Tang, Alex Aronov
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6784195
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 31, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao
  • Compositions useful as inhibitors of rock and other protein kinases
    Publication number: 20040122016
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 30, 2003
    Publication date: June 24, 2004
    Inventors: Jingrong Cao, Huai Gao, Jeremy Green, Craig Marhefka
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 6743791
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: June 1, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Qing Tang, Alex Aronov
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20040102506
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: October 17, 2003
    Publication date: May 27, 2004
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6699865
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: March 2, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang
  • Inhibitors of c-JUN N terminal kinases (JNK) and other protein kinases
    Patent number: 6693108
    Abstract: The present invention provides compounds of formula I: where R1 is H, CONH2, T(n)—R, or T(n)—Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 17, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Guy Bemis, Anne-Laure Grillot, Mark Ledeboer, Francesco G. Salituro, Edmund Harrington, Huai Gao, Christopher Baker, Jingrong Cao, Michael Hale
  • Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
    Publication number: 20040023963
    Abstract: The present invention provides compounds of formula I: 1
    Type: Application
    Filed: May 14, 2003
    Publication date: February 5, 2004
    Inventors: Jingrong Cao, Jeremy Green, Young-Choon Moon, Jian Wang, Mark Ledeboer, Edmund Harrington, Huai Gao
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20030225151
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: January 2, 2003
    Publication date: December 4, 2003
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang